Báo cáo y học: The Pediatric Obsessive-Compulsive Disorder Treatment Study II: rationale, design and methods

Tuyển tập các báo cáo nghiên cứu về y học được đăng trên tạp chí y học Critical Care giúp cho các bạn có thêm kiến thức về ngành y học đề tài: c. | Child and Adolescent Psychiatry and Mental Health BioMed Central Research Change in the direct cost of treatment for children and adolescents with hyperkinetic disorder in Germany over a period of four years Peter M Wehmeier 1 Alexander Schacht1 and Aribert Rothenberger2 Open Access Address 1Medical Department Lilly Deutschland GmbH Bad Homburg Germany and 2Department of Child and Adolescent Psychiatry University of Gottingen Gottingen Germany Email Peter M Wehmeier - wehmeier_peter@ Alexander Schacht - schacht_alexander@ Aribert Rothenberger - arothen@ Corresponding author Published 28 January 2009 Received 18 November 2008 Child and Adolescent Psychiatry and Mental Health 2009 3 3 doi 1753-2000-3-3 Accepted 28 January 2009 This article is available from http content 3 1 3 2009 Wehmeier et al licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License http licenses by which permits unrestricted use distribution and reproduction in any medium provided the original work is properly cited. Abstract Background In many developed countries the treatment of hyperkinetic disorder or ADHD consumes a considerable amount of resources. The primary aim of this study was to determine change in the direct cost of treatment for children and adolescents with hyperkinetic disorder in Germany over time and compare the cost with the cost of treatment for two physical disorders epilepsy and asthma. Methods The German Federal Statistical Office provided data on the direct cost of treating hyperkinetic disorder epilepsy and asthma in Germany for 2002 2004 and 2006. The direct costs of treatment incurred by hyperkinetic disorder in these years were compared with those incurred by epilepsy and asthma. Results The total direct cost of treatment for the hyperkinetic disorder was 177 million in 2002 234 million in 2004 and 341 million in 2006. The .